The Schick Foundation has submitted the final requirements for getting approval from the FDA for Blue Green Algae. Final approval is expected from the FDA in 4 weeks. If it is approved it will be one of the first supplements or botanicals to have FDA approval for study. The Foundation has already developed a protocol for testing Blue Green Algae in HIV+ patients who are virologically suppressed by antiretroviral agents, preferably Atripla, and are treatment Naive except for beginning Atripla within the last 6 months.
The protocol might also help determine at what level of CD 4 count Blue green algae might be successful. The protocol is stratifying patients from CD 4 counts of 200-350, 350-500, and patients who have greater than 500 CD 4 counts/ml. The results of the study once started should take about 6 months, but the markers we are following, pro-viral DNA, viral load, CD 4 count, CD 4%, CD 8 count CD 8%, D-Dimer, C Reactive Protein, and others might give an indication of success much earlier than 6 months.
The Schick foundation had already gotten approval for presenting a poster at the large AMFAR meeting in New Orleans on :November 29. The meeting extends from November 28-December 1. The title of the original poster was The Role of APHANIZOMENON FLOS-ACQAE in treating HIV+ virologically suppressed patients with HAART:. The original submission was on 1 patient whom we term patient O. We continued to present updated material thru 14 weeks and as a result the poster was upgraded to a full presentation to this large meeting. The significant findings already show that we have found that APHANIZOMENON FLOS-ACQAE, abbreviated AFA or Blue green algae, statistically improved patient O's CD 4 count, and CD 4%, while other markers named above are stable. CD 34 was elevated showing that the product which increases the release of bone marrow stem cells from the person's bone marrow 30% 2 hours after ingestion of 1000 mg of the supplement is working. We expect to have more data especially with respect to how AFA might be working at the meeting in New Orleans.
The Schick Foundation has added 2 new members to their consultant staff. Dr. Annika Hylmo a PHD, and Dr. Michael Hamrell also a PHD give the foundation a greater presence in science, with one of these people, Dr. Hamrell, being previously associated with the FDA, and the NIH.
To see whether the protocols that the Schick Foundation has developed donate on line to the web sites www.schickfoundation.org or www.schickresearch.com . You could also submit a check to the Peter Schick Foundation at 1223 Wilshire Blvd.#1007, Santa Monica Ca., 90403. We are approaching the end of the year where people think about charitable donations and what better cause than to donate to a 501C3 foundation that has a chance to end the greatest pandemic in deaths since early times the world has seen.
skip to main |
skip to sidebar
At The Peter Schick Foundation we have a vision, that someday soon, both long time and newly infected HIV patients will have access to a treatment that will eradicate HIV and AIDS virus.
Posts
